

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Spironolactone-d₃

Item No. 43592

Formal Name: $(7\alpha,17\alpha)$ -7-(acetylthio-d₃)-17-hydroxy-

3-oxo-pregn-4-ene-21-carboxylic acid-

γ-lactone

Synonym: SC-9420-d₂ MF: $C_{24}H_{29}D_3O_4S$

FW: 419.6


Chemical Purity: ≥95% (Spironolactone)

Deuterium

Incorporation: ≥99% deuterated forms (d_1-d_3) ; ≤1% d_0

Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Spironolactone-d₃ is intended for use as an internal standard for the quantification of spironolactone by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Spironolactone-d₃ is supplied as a solid. A stock solution may be made by dissolving the spironolactone-d₃ in the solvent of choice, which should be purged with an inert gas. Spironolactone-d₃ is soluble (≥10 mg/ml) in methanol, acetonitrile, and DMSO.

Description

Spironolactone is a steroidal mineralocorticoid receptor antagonist (IC_{50} = 24 nM) and a diuretic.¹ It is selective for the mineralocorticoid receptor over the glucocorticoid receptor (IC_{50} = 2,410 nM) but also binds to the androgen receptor and progesterone receptor (IC₅₀s = 77 and 743 nM, respectively). In vivo, spironolactone (37.5 mg/kg per day) administered in combination with lisinopril preserves ejection fraction in mice and reduces myocardial fibrosis in a mouse model of Duchenne muscular dystrophy (DMD).² Formulations containing spironolactone have been used in the treatment of hypertension and heart failure.

References

- 1. Kolkhof, P., Jaisser, F., Kim, S.-Y., et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside. Handb. Exp. Pharmacol. 243, 271-305 (2017).
- 2. Rafael-Fortney, J.A., Chimanji, N.S., Schill, K.E., et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124(5), 582-588 (2011).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 05/15/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM